Raymond James Financial’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Raymond James Financial’s Portfolio LYRA Stock Details LYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$72	–	5978
2025 Q2	$72	Buy	+8	New	+$66	﹤0.01%	6863

Other funds holding LYRA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's LYRA Position: Q3 2025 in Review

Raymond James Financial sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2025, closing a stake of 8 shares — an estimated $72 sold.

Raymond James Financial first reported a position in LYRA in Q2 2025 and held it in 1 quarter. The position peaked at $72 in Q2 2025. 26 funds tracked by Wall St. Rank hold LYRA as of Q3 2025.

Raymond James Financial reported no remaining LYRA THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 8 LYRA THERAPEUTICS INC shares in Q3 2025, an estimated $72.
Raymond James Financial first reported a position in LYRA THERAPEUTICS INC in Q2 2025 and held it in 1 quarter.
Raymond James Financial's LYRA THERAPEUTICS INC position peaked at $72 in Q2 2025.
26 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.